These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 21817186)

  • 41. Drug-drug interaction between itraconazole and the protease inhibitor lopinavir/ritonavir.
    Hills-Nieminen C; Hughes CA; Houston S; Shafran SD
    Ann Pharmacother; 2009 Dec; 43(12):2117-20. PubMed ID: 19934385
    [TBL] [Abstract][Full Text] [Related]  

  • 42. HIV infection and high-density lipoprotein: the effect of the disease vs the effect of treatment.
    Rose H; Woolley I; Hoy J; Dart A; Bryant B; Mijch A; Sviridov D
    Metabolism; 2006 Jan; 55(1):90-5. PubMed ID: 16324925
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patients.
    von Hentig N; Babacan E; Staszewski S; Stürmer M; Doerr HW; Lötsch J
    Antivir Ther; 2007; 12(8):1237-46. PubMed ID: 18240863
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lopinavir/ritonavir pharmacokinetics, efficacy, and safety in HIV and hepatitis B or C coinfected adults without symptoms of hepatic impairment.
    Khaykin P; Kotzerke P; Stephan C; Nisius G; Bickel M; Haberl A; Stürmer M; Kurowski M; Brodt R; von Hentig N
    Ther Drug Monit; 2014 Apr; 36(2):192-201. PubMed ID: 24632753
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
    Maillard A; Chapplain JM; Tribut O; Bentué-Ferrer D; Tattevin P; Arvieux C; Michelet C; Ruffault A
    J Clin Virol; 2007 Feb; 38(2):131-8. PubMed ID: 17208042
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CYP3A5 genotype has no impact on plasma trough concentrations of lopinavir and ritonavir in HIV-infected subjects.
    Estrela RC; Santoro AB; Barroso PF; Tuyama M; Suarez-Kurtz G
    Clin Pharmacol Ther; 2008 Aug; 84(2):205-7. PubMed ID: 18288082
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure.
    Raguin G; Chêne G; Morand-Joubert L; Taburet AM; Droz C; Le Tiec C; Clavel F; Girard PM;
    Antivir Ther; 2004 Aug; 9(4):615-25. PubMed ID: 15456093
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Metabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy.
    Arpadi S; Shiau S; Strehlau R; Martens L; Patel F; Coovadia A; Abrams EJ; Kuhn L
    Arch Dis Child; 2013 Apr; 98(4):258-64. PubMed ID: 23220209
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Atherogenic properties of LDL particles after switching from Truvada or Kivexa plus lopinavir/r to lamivudine plus lopinavir/r: OLE-MET substudy.
    Saumoy M; Tiraboschi JM; Ordoñez-Llanos J; Ribera E; Domingo P; Mallolas J; Curto J; Gatell JM; Podzamczer D
    HIV Clin Trials; 2017 Mar; 18(2):49-53. PubMed ID: 28081673
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Increased bone resorption during tenofovir plus lopinavir/ritonavir therapy in Chinese individuals with HIV.
    Hsieh E; Fraenkel L; Xia W; Hu YY; Han Y; Insogna K; Yin MT; Xie J; Zhu T; Li T
    Osteoporos Int; 2015 Mar; 26(3):1035-44. PubMed ID: 25224293
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Zidovudine/lamivudine for HIV-1 infection contributes to limb fat loss.
    van Vonderen MG; van Agtmael MA; Hassink EA; Milinkovic A; Brinkman K; Geerlings SE; Ristola M; van Eeden A; Danner SA; Reiss P;
    PLoS One; 2009 May; 4(5):e5647. PubMed ID: 19479079
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cardiovascular disease risk factors in HIV-infected women after initiation of lopinavir/ritonavir- and nevirapine-based antiretroviral therapy in Sub-Saharan Africa: A5208 (OCTANE).
    Shaffer D; Hughes MD; Sawe F; Bao Y; Moses A; Hogg E; Lockman S; Currier J
    J Acquir Immune Defic Syndr; 2014 Jun; 66(2):155-63. PubMed ID: 24562349
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Challenges of lopinavir/ritonavir in the chronicity of human immunodeficiency virus infection].
    Aguirrebengoa K
    Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():26-30. PubMed ID: 25542873
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hyperlipidaemia in HIV-infected patients on lopinavir/ritonavir monotherapy in resource-limited settings.
    Matoga MM; Hosseinipour MC; Aga E; Ribaudo HJ; Kumarasamy N; Bartlett J; Hughes MD;
    Antivir Ther; 2017; 22(3):205-213. PubMed ID: 27740537
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Side effects and tolerability of post-exposure prophylaxis with zidovudine, lamivudine, and lopinavir/ritonavir: a comparative study with HIV/AIDS patients.
    Cai J; Xiao J; Zhang Q
    Chin Med J (Engl); 2014; 127(14):2632-6. PubMed ID: 25043080
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hair loss induced by lopinavir-ritonavir.
    Borrás-Blasco J; Belda A; Rosique-Robles D; Casterá E; Abad J; Amorós-Quiles I
    Pharmacotherapy; 2007 Aug; 27(8):1215-8. PubMed ID: 17655521
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ritonavir-containing regimens.
    Gutiérrez F; Padilla S; Navarro A; Masiá M; Hernández I; Ramos J; Esteban A; Martin-Hidalgo A
    J Acquir Immune Defic Syndr; 2003 Aug; 33(5):594-600. PubMed ID: 12902803
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Perinatal lopinavir + ritonavir: adrenal insufficiency.
    Prescrire Int; 2012 Mar; 21(125):71. PubMed ID: 22428190
    [No Abstract]   [Full Text] [Related]  

  • 59. ABCB1 polymorphisms and the concentrations of lopinavir and ritonavir in blood, semen and saliva of HIV-infected men under antiretroviral therapy.
    Estrela Rde C; Ribeiro FS; Barroso PF; Tuyama M; Gregório SP; Dias-Neto E; Struchiner CJ; Suarez-Kurtz G
    Pharmacogenomics; 2009 Feb; 10(2):311-8. PubMed ID: 19207033
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens.
    Anastos K; Lu D; Shi Q; Tien PC; Kaplan RC; Hessol NA; Cole S; Vigen C; Cohen M; Young M; Justman J
    J Acquir Immune Defic Syndr; 2007 May; 45(1):34-42. PubMed ID: 17460470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.